Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Neurology Clinic PC

Neither a doctor nor a teaching hospital

Research payments

$21,653,449

340 payments

Through program year 2025, Neurology Clinic PC is reported as receiving $21,653,449 in research payments, across 340 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $1,675,494 98
2024 Research $6,385,599 85
2023 Research $5,806,369 91
2022 Research $5,495,861 56
2021 Research $2,078,059 2
2020 Research $81,483 2
2019 Research $130,585 6

Breakdown

Who paid Research payments · program years 2019–2025
  1. Eli Lilly and Company $14,684,959 42 payments
  2. Biogen, Inc. $2,592,358 8 payments
  3. Eisai Inc. $2,548,687 46 payments
  4. Genentech, Inc. $1,078,482 86 payments
  5. F. Hoffmann-La Roche AG $276,460 78 payments
  6. Novartis Pharmaceuticals Corporation $259,173 7 payments
  7. Harmony Biosciences LLC $64,934 24 payments
  8. Alkermes, Inc. $43,201 39 payments
  9. Avid Radiopharmaceuticals, Inc. $38,997 1 payment
  10. Genzyme Corporation $31,020 3 payments
Studies the money was for Research payments · program years 2019–2025
  1. Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimers Disease $6,533,208 8 payments
  2. A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease $2,548,687 46 payments
  3. A Study of Different Donanemab (Ly3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (Trailblazer-Alz 6) $1,992,594 3 payments
  4. Assessment of Safety, Tolerability, and Efficacy Measured By Amyloid Reduction of Ly3372993 in Early Symptomatic Alzheimer's Disease $1,895,810 5 payments
  5. A Study of Donanemab (Ly3002813) in Participants With Early Alzheimer's Disease (Trailblazer-Alz 2) $1,790,064 2 payments
  6. A Phase 3b/4 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Verify the Clinical Benefit of Aducanumab (BIIB037) in Participants With Alzheimer's Disease $1,175,159 4 payments
  7. A Study of Different Donanemab (Ly3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (Trailblazer-Alz 6) $1,158,943 2 payments
  8. Phase 3b Open-Label, Multicenter, Safety Study of BIIB037 (aducanumab) in Subjects with Alzheimer's disease Who Had Previously Participated in the Aducanumab Studies221AD103, 221AD301, 221AD302 and 221AD205 $763,041 1 payment
  9. Phase 3b Open-Label, Multicenter, Safety Study of BIIB037 (aducanumab) in Subjects with Alzheimers disease Who Had Previously Participated in the Aducanumab Studies221AD103, 221AD301, 221AD302 and 221AD205 $654,157 3 payments
  10. Assessment of Safety Tolerability and Efficacy Measured By Amyloid Reduction of Ly3372993 in Early Symptomatic Alzheimer's Disease $471,289 2 payments
What the money was spent on Research payments · program years 2019–2025
  1. Other $1,000 1 payment

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record